Assessing the effect of hyperbaric oxygen therapy in breast cancer patients with late radiation toxicity (HONEY trial): a trial protocol using a trial within a cohort design

M C T Batenburg, H J G D van den Bongard, C E Kleynen, W Maarse, A Witkamp, M Ernst, A Doeksen, T van Dalen, M Sier, E J P Schoenmaeckers, I O Baas, H M Verkooijen, M C T Batenburg, H J G D van den Bongard, C E Kleynen, W Maarse, A Witkamp, M Ernst, A Doeksen, T van Dalen, M Sier, E J P Schoenmaeckers, I O Baas, H M Verkooijen

Abstract

Background: Breast cancer treatment with radiotherapy can induce late radiation toxicity, characterized by pain, fibrosis, edema, impaired arm mobility, and poor cosmetic outcome. Hyperbaric oxygen therapy (HBOT) has been proposed as treatment for late radiation toxicity; however, high-level evidence of effectiveness is lacking. As HBOT is standard treatment and reimbursed by insurers, performing classic randomized controlled trials is difficult. The "Hyperbaric OxygeN therapy on brEast cancer patients with late radiation toxicity" (HONEY) trial aims to evaluate the effectiveness of HBOT on late radiation toxicity in breast cancer patients using the trial within cohorts (TwiCs) design.

Methods: The HONEY trial will be conducted within the Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaluation (UMBRELLA). Within UMBRELLA, breast cancer patients referred for radiotherapy to the University Medical Centre Utrecht are eligible for inclusion. Patients consent to collection of clinical data and patient-reported outcomes and provide broad consent for randomization into future intervention studies. Patients who meet the HONEY in- and exclusion criteria (participation ≥ 12 months in UMBRELLA, moderate/severe breast or chest wall pain, completed primary breast cancer treatment except hormonal treatment, no prior treatment with HBOT, no contraindications for HBOT, no clinical signs of metastatic or recurrent disease) will be randomized to HBOT or control group on a 2:1 ratio (n = 120). Patients in the control group will not be informed about participation in the trial. Patients in the intervention arm will undergo 30-40 HBOT treatment sessions in a high pressure chamber (2.4 atmospheres absolute) where they inhale 100% oxygen through a mask. Cohort outcome measures (i.e., physical outcomes, quality of life, fatigue, and cosmetic satisfaction) of the HBOT group will be compared to the control group at 3 months follow-up.

Discussion: This pragmatic trial within the UMBELLA cohort was designed to evaluate the effectiveness of HBOT on late radiation toxicity in breast cancer patients using the TwiCs design. Use of the TwiCs design is expected to address issues encountered in classic randomized controlled trials, such as contamination (i.e., HBOT in the control group) and disappointment bias, and generate information about acceptability of HBOT.

Trial registration: ClinicalTrials.gov. NCT04193722 . Registered on 10 December 2019.

Keywords: Breast cancer; Hyperbaric oxygen therapy; Late toxicity; Patient-reported outcomes; Radiotherapy; Trials within cohorts.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Design of the UMBRELLA HONEY trial; a trial within cohorts design (TwiCs design), figure adapted from Relton et al. [10]
Fig. 2
Fig. 2
Schedule of enrollment, interventions, and assessments in the HONEY study

References

    1. Nederlandse Kankerregistratie. No Title [Internet]. IKNL. 2020 [cited 2020 Mar 20]. Available from: .
    1. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–2106. doi: 10.1016/S0140-6736(05)67887-7.
    1. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–1716. doi: 10.1016/S0140-6736(11)61629-2.
    1. Marx RE, Ehler WJ, Tayapongsak P, Pierce LW. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg. 1990;160(5):519–524. doi: 10.1016/S0002-9610(05)81019-0.
    1. Teguh DN, Bol Raap R, Struikmans H, Verhoef C, Koppert LB, Koole A, et al. Hyperbaric oxygen therapy for late radiation-induced tissue toxicity: prospectively patient-reported outcome measures in breast cancer patients. Radiat Oncol. 2016;11(1):130. doi: 10.1186/s13014-016-0700-0.
    1. Carl UM, Feldmeier JJ, Schmitt G, Hartmann KA. Hyperbaric oxygen therapy for late sequelae in women receiving radiation after breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2001;49(4):1029–1031. doi: 10.1016/S0360-3016(00)01515-7.
    1. Hoggan BLCAL. Systematic review of hyperbaric oxygen therapy for the treatment of non-neurological soft tissue radiation-related injuries. Support Care Cancer. 2014;22:1715–1726. doi: 10.1007/s00520-014-2198-z.
    1. Heyboer M, Sharma D, Santiago W, McCulloch N. Hyperbaric oxygen therapy: side effects defined and quantified. Adv Wound Care. 2017;6(6):210–224. doi: 10.1089/wound.2016.0718.
    1. Teguh DN, Levendag PC, Noever I, Voet P, van der Est H, van Rooij P, et al. Early hyperbaric oxygen therapy for reducing radiotherapy side effects: early results of a randomized trial in oropharyngeal and nasopharyngeal cancer. Int J Radiat Oncol Biol Phys. 2009;75(3):711–716. doi: 10.1016/j.ijrobp.2008.11.056.
    1. Relton C, Torgerson D, O’Cathain A, Nicholl J, Renton C, Torgerson D, et al. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ. 2010;340(mar19_1):c1066. doi: 10.1136/bmj.c1066.
    1. Young-Afat DA, van Gils CH, van den Bongard HJGD, Verkooijen HM. The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results. Breast Cancer Res Treat. 2017;164(2):445–450. doi: 10.1007/s10549-017-4242-4.
    1. Young-Afat DA, Verkooijen HAM, Van Gils CH, Van Der Velden JM, Burbach JP, Elias SG, et al. Staged-informed consent in the cohort multiple randomized controlled trial design. Epidemiology. 2016;27(3):389–392. doi: 10.1097/EDE.0000000000000435.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365.
    1. U.S. Department of health and human services. Common Terminology Criteria of Adverse Events (CTCAE) version 4.3. 2010. Available from .
    1. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009;124(2):345–353. doi: 10.1097/PRS.0b013e3181aee807.
    1. Cano SJ, Klassen AF, Scott AM, Cordeiro PG, Pusic AL. The BREAST-Q: Further validation in independent clinical samples. Plast Reconstr Surg. 2012;129(2):293–302. doi: 10.1097/PRS.0b013e31823aec6b.
    1. Edmonds C. Diving and subaquatic medicine, 5 ed., CRC Press, 2016, p. 86-87.
    1. PDP Optimizing shoulder function in cancer patients through the use of novel group-based pilot programming. Arch Phys Med Rehabil. 2017;98(10):e88.
    1. Svalestad J, Thorsen E, Vaagbo G, Hellem S. Effect of hyperbaric oxygen treatment on oxygen tension and vascular capacity in irradiated skin and mucosa. Int J Oral Maxillofac Surg. 2014;43(1):107–112. doi: 10.1016/j.ijom.2013.07.006.
    1. Vos EL, Nieboer D, Verhoef C, Corten EML, Koppert LB. Evaluation of cosmetic outcome following breast-conserving therapy in trials : panel versus digitalized analysis and the role of PROMs. Breast J. 2018;24(4):519-525.
    1. Hewitt CE, Torgerson DJ, Miles JNV. Is there another way to take account of noncompliance in randomized controlled trials? Cmaj. 2006;175(4):347–348. doi: 10.1503/cmaj.051625.
    1. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med. 1997;16(9):1017–1029. doi: 10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>;2-V.
    1. Vergouwe Y, Royston P, Moons KGM, Altman DG. Development and validation of a prediction model with missing predictor data: a practical approach. J Clin Epidemiol. 2010;63(2):205–214. doi: 10.1016/j.jclinepi.2009.03.017.
    1. Moons KGM, Donders RART, Stijnen T, Harrell FE. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol. 2006;59(10):1092–1101. doi: 10.1016/j.jclinepi.2006.01.009.
    1. Sterne J, White I, Carlin J, Spratt M, Royston P, Kenward M. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. doi: 10.1136/bmj.b2393.
    1. White I, Royston P, Wood A. Multiple imputation using chained equations:issues and guidance for practice. Stat Med. 2011;30:377e9.
    1. Bonnetain F, Fiteni F, Efficace F, Anota A. Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. J Clin Oncol. 2016;34(16):1953–1956. doi: 10.1200/JCO.2014.56.7974.
    1. Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH, EORTC Late Effects Working Group Overview of late effects normal tissues (LENT) scoring system. Radiother Oncol. 1995;35(1):9–10. doi: 10.1016/0167-8140(95)97447-L.
    1. Clarke RE, Tenorio LMC, Hussey JR, Toklu AS, Cone DL, Hinojosa JG, et al. Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys. 2008;72(1):134–143. doi: 10.1016/j.ijrobp.2007.12.048.
    1. Brouwers PJAM, van Loon J, Houben RMA, Paulissen J, Engelen SME, Heuts M, et al. Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10years of follow up. Radiother Oncol. 2018;126(1):163–169. doi: 10.1016/j.radonc.2017.08.004.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner